SAN DIEGO, March 7, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, today
announced the appointment of Jim
Daly to its board of directors. Mr. Daly is a
biopharmaceutical executive with 30 years of experience leading
U.S. and global businesses.
"We are very pleased to have Jim join our board," said Dr.
Helen Torley, president and chief
executive officer. "With extensive experience in launching and
building major brands, particularly in oncology, he will serve as a
valuable resource to our directors and executive leadership team as
we move toward the potential commercialization of our
investigational drug PEGPH20."
Mr. Daly previously served as executive vice president and chief
commercial officer at Incyte Corporation from 2012 to 2015. Prior
to Incyte, Daly was senior vice president of North America
Commercial Operations, Global Marketing and Commercial Development
for Amgen, with P&L responsibility for all U.S. and Canadian
businesses. Daly also served as vice president and general manager
for Amgen's Oncology Business Unit.
Mr. Daly began his career in the pharmaceutical industry at
GlaxoSmithKline where he held positions of increasing
responsibility, including senior vice president and general manager
of the company's Respiratory and Anti-infective Business Unit, as
well as senior vice president of U.S. Marketing. He earned a
Bachelor of Science degree in Pharmacy and Master of Business
Administration from the State University of
New York at Buffalo.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning the Company's future expectations
and plans for growth in 2016, the development and commercialization
of product candidates and the potential benefits and attributes of
such product candidates) that involve risk and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected fluctuations or changes in revenues, including revenues
from collaborators, unexpected results or delays in development of
product candidates and regulatory review, regulatory approval
requirements, unexpected adverse events and competitive conditions.
These and other factors that may result in differences are
discussed in greater detail in the Company's Annual Report on Form
10-K filed with the Securities and Exchange Commission on
February 29, 2016.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-appoints-jim-daly-to-board-of-directors-300231503.html
SOURCE Halozyme Therapeutics, Inc.